9,620 Shares in Cambrex Co. (CBM) Purchased by Municipal Employees Retirement System of Michigan
Municipal Employees Retirement System of Michigan acquired a new position in Cambrex Co. (NYSE:CBM) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 9,620 shares of the biotechnology company’s stock, valued at approximately $363,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Teachers Advisors LLC raised its stake in shares of Cambrex by 19.8% in the 3rd quarter. Teachers Advisors LLC now owns 73,543 shares of the biotechnology company’s stock worth $5,030,000 after buying an additional 12,166 shares in the last quarter. Epoch Investment Partners Inc. bought a new stake in shares of Cambrex in the 4th quarter worth $5,046,000. Global Alpha Capital Management Ltd. raised its stake in shares of Cambrex by 10.4% in the 4th quarter. Global Alpha Capital Management Ltd. now owns 253,109 shares of the biotechnology company’s stock worth $9,557,000 after buying an additional 23,800 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Cambrex in the 3rd quarter worth $321,000. Finally, MetLife Investment Advisors LLC raised its stake in shares of Cambrex by 56.3% in the 3rd quarter. MetLife Investment Advisors LLC now owns 23,719 shares of the biotechnology company’s stock worth $1,622,000 after buying an additional 8,539 shares in the last quarter.
A number of analysts have recently commented on CBM shares. Zacks Investment Research downgraded Cambrex from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Craig Hallum dropped their price objective on Cambrex from $71.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, February 14th. ValuEngine downgraded Cambrex from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 31st. Finally, Jefferies Financial Group downgraded Cambrex from a “buy” rating to a “hold” rating and set a $43.00 price objective on the stock. in a research note on Friday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Cambrex currently has a consensus rating of “Buy” and an average price target of $48.75.
Shares of Cambrex stock opened at $38.22 on Thursday. The firm has a market cap of $1.28 billion, a PE ratio of 13.80, a P/E/G ratio of 3.33 and a beta of 2.40. The company has a current ratio of 3.93, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46. Cambrex Co. has a 12-month low of $33.80 and a 12-month high of $69.43.
Cambrex (NYSE:CBM) last announced its earnings results on Wednesday, February 13th. The biotechnology company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The company had revenue of $212.30 million for the quarter, compared to analyst estimates of $182.49 million. Cambrex had a return on equity of 14.74% and a net margin of 17.37%. Cambrex’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 earnings per share. Equities research analysts predict that Cambrex Co. will post 1.14 EPS for the current fiscal year.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Recommended Story: Current Ratio
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.